Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E31.38 EPS (ttm)10.32 Insider Own1.20% Shs Outstand107.77M Perf Week-2.80%
Market Cap34.90B Forward P/E15.51 EPS next Y20.88 Insider Trans-4.59% Shs Float79.06M Perf Month-15.51%
Income1.20B PEG2.55 EPS next Q4.30 Inst Own70.50% Short Float2.45% Perf Quarter-15.76%
Sales5.87B P/S5.94 EPS this Y34.30% Inst Trans-0.31% Short Ratio2.00 Perf Half Y-32.13%
Book/sh57.41 P/B5.64 EPS next Y14.74% ROA14.40% Target Price426.32 Perf Year-10.28%
Cash/sh13.08 P/C24.76 EPS next 5Y12.28% ROE21.20% 52W Range313.53 - 543.55 Perf YTD-13.86%
Dividend- P/FCF33.74 EPS past 5Y8.90% ROI17.50% 52W High-40.42% Beta1.52
Dividend %- Quick Ratio3.40 Sales past 5Y33.60% Gross Margin93.20% 52W Low3.29% ATR13.04
Employees6200 Current Ratio3.80 Sales Q/Q29.00% Oper. Margin35.40% RSI (14)39.05 Volatility2.87% 4.60%
OptionableYes Debt/Eq0.11 EPS Q/Q-31.30% Profit Margin20.40% Rel Volume0.70 Prev Close315.82
ShortableYes LT Debt/Eq0.11 EarningsFeb 08 BMO Payout0.00% Avg Volume967.87K Price323.86
Recom2.40 SMA20-5.76% SMA50-11.31% SMA200-24.99% Volume673,440 Change2.55%
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Feb-23-18 08:55AM  Corcept's (CORT) Earnings and Sales Meet Estimates in Q4 Zacks
Feb-22-18 07:30AM  Detailed Research: Economic Perspectives on Intersect ENT, Granite Construction, Spok, Regeneron Pharmaceuticals, SunTrust Banks, and Interpublic Group of Companies What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-21-18 11:10AM  Regeneron shares slip after Canaccord downgrades stock, slashes price target 32% MarketWatch
11:07AM  Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges Benzinga
10:01AM  Regeneron's Eylea Has Mysterious Rise in Side Effect Reports Bloomberg
Feb-20-18 08:44AM  Novavax (NVAX) in Focus: Stock Moves 8.3% Higher Zacks
08:07AM  The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal Zacks
Feb-16-18 04:00PM  Top Research Reports for Novo Nordisk, TJX Companies & Cigna Zacks
Feb-15-18 03:21PM  The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs Forbes
Feb-13-18 03:03PM  Stocks Up, These Groups Smoke Indexes; Buy This Bitcoin Fund Or Wait? Investor's Business Daily -5.28%
12:20PM  3 Biotech Stocks Facing Steep Declines Investopedia
06:28AM  Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)
Feb-12-18 04:26PM  Regeneron Could Benefit From 'Lackluster' Data Presented By These Rivals Investor's Business Daily
08:30AM  Todays Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Gilead Sciences ACCESSWIRE
07:00AM  Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial PR Newswire
Feb-09-18 10:46AM  Analyst: Regeneron Is Undervalued By The Street Benzinga
07:20AM  Blog Exposure - ArQule Signed License Agreement with Roivant Sciences to Develop Derazantinib In China ACCESSWIRE
Feb-08-18 04:32PM  Regeneron Dips In Sympathy With Biotechs Despite Quarterly Beat Investor's Business Daily
04:02PM  Should You Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) To Continue Delivering An ROE Of 24.25%? Simply Wall St.
11:45AM  Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow Zacks
11:19AM  Regeneron CEO says fears over Eylea "greatly exaggerated" Reuters
08:08AM  Regeneron (REGN) Tops Q4 Earnings & Sales Zacks
08:07AM  Stocks making the biggest moves premarket: TWTR, REGN, YUM, GRUB, CVS, TMUS & more CNBC
08:06AM  Regeneron stock lifts 4% after Q4 profit, revenue beats MarketWatch
06:53AM  Regeneron beats Street 4Q forecasts Associated Press
06:40AM  Regeneron Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:37AM  Regeneron posts 31 percent drop in quarterly profit Reuters
06:30AM  Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results PR Newswire
Feb-07-18 04:39PM  Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe Investor's Business Daily
12:20PM  Sanofi (SNY) Q4 2017 Earnings Conference Call Transcript Motley Fool
10:12AM  REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings? Zacks
Feb-06-18 12:01PM  The Diseases We Arent CuringAnd Why Fortune
Feb-05-18 10:09AM  Will Regeneron (REGN) Disappoint Investors in Q4 Earnings? Zacks
Jan-30-18 02:34PM  Regeneron Pharmaceuticals Inc (REGN)s Dupixent Has Multi-Billion-Dollar Potential: Polen Capital Insider Monkey
Jan-23-18 04:05PM  Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018 PR Newswire
12:01PM  Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018 PR Newswire
09:42AM  Regeneron's Dupixent Receives MHLW Nod for Label Expansion Zacks
Jan-22-18 07:46PM  Why 2017 Was a Year to Forget for Regeneron Pharmaceuticals, Inc. Motley Fool
07:00AM  Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis PR Newswire
Jan-17-18 09:03AM  Repatha Could Significantly Drive Amgens Revenue Growth in 2018 Market Realist
Jan-12-18 10:06AM  That Biotech M&A Wave? More like a Trickle
Jan-11-18 07:02PM  Cramer's lightning round: People might be bailing on Rege... CNBC Videos
06:51PM  Cramer's lightning round: People might be bailing on Regeneron, but it's a buy CNBC
10:19AM  Can Biotech Keep Last Year's Momentum Alive in 2018? Zacks
07:33AM  How Mylans Europe Segment Performed in 3Q17 Market Realist
Jan-10-18 05:20PM  How Did Bioverativ Perform in 3Q17? Market Realist
02:35PM  A Look at Ionis Pharmaceuticals January 2018 Valuation Market Realist
07:23AM  Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-09-18 05:47PM  Regeneron CEO talks drug pricing and tax reform CNBC Videos
05:00PM  3 Ways to trade biotech CNBC Videos
01:55PM  Finally, a Cure for Legalese The Wall Street Journal
10:23AM  Hows Incytes Valuation in January 2018? Market Realist
10:00AM  Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab Zacks
08:06AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
12:57AM  Rivals Help Fund Regenerons Gene-Sequencing Effort The Wall Street Journal
Jan-08-18 03:20PM  Regeneron forms consortium to accelerate gene sequencing project Reuters
09:05AM  Sanofi and Regeneron boost investment in cancer drug cemiplimab Reuters
08:12AM  What Are Analysts Saying About Regeneron Pharmaceuticals Incs (NASDAQ:REGN) Future? Simply Wall St.
07:04AM  Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs PR Newswire
07:02AM  Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs GlobeNewswire
07:00AM  Rivals Help Fund Regeneron's Gene-Sequencing Effort The Wall Street Journal
07:00AM  Regeneron forms consortium to accelerate gene sequencing project Reuters
07:00AM  Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank PR Newswire
Jan-04-18 08:35AM  Momenta & Mylan to Initiate Trial on Biosimilar of Eylea Zacks
Jan-03-18 05:40PM  Momenta, Mylan plan trial of biosimilar to Regeneron eye drug Reuters
Jan-02-18 04:08PM  Does Regeneron Pharma Have A Potential Blockbuster In 2018? Investor's Business Daily
09:20AM  Breakthrough drugs offer hope for the 360 million people with hearing loss CNBC
Dec-28-17 07:45PM  Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Expensive For A Reason? A Look At The Intrinsic Value Simply Wall St.
Dec-27-17 09:30AM  Regeneron Announces Presentation at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-26-17 12:01PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-22-17 09:27AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017 Capital Cube
Dec-20-17 06:30AM  Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy Zacks
Dec-19-17 09:53AM  Regeneron in Strategic Immuno-Oncology Collaboration With ISA Zacks
07:28AM  The Zacks Analyst Blog Highlights: Disney, Kraft Heinz, Caterpillar, Humana and Regeneron Zacks
Dec-18-17 01:01AM  ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration GlobeNewswire
01:00AM  Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration PR Newswire
Dec-15-17 02:05PM  Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations Zacks
01:20PM  Beware: Price Wars For Big Pharma, Biotech Companies On Horizon Investor's Business Daily
11:15AM  Biotech Celgene May Rise 35% In 2018 Investopedia
Dec-14-17 07:11PM  Cramer's lightning round: Buy Regeneron, it's not getting... CNBC Videos
06:46PM  Cramer's lightning round: Buy Regeneron, it's not getting the credit it deserves CNBC
02:00PM  Sanofi Wants to Go It Alone -- Good Luck With That Bloomberg
12:38PM  Regenerons Kevzara Approved for Treatment of Rheumatoid Arthritis Market Realist
12:38PM  Regenerons Dupixent Approved for Atopic Dermatitis Market Realist
Dec-13-17 08:45PM  Will This Drug Kick-Start Regeneron Pharmaceuticals Shares? Motley Fool
05:45PM  Regeneron, Sanofi Report Positive Top Line Skin Cancer Data Zacks
11:25AM  Intercept: The Best of the Biotechs?
10:24AM  France's Sanofi pins hopes on new drugs after setbacks Reuters
06:24AM  Where Regeneron Pharmaceuticals Inc (undefined:REGN) Stands In Terms Of Earnings Growth Against Its Industry Simply Wall St.
04:42AM  France's Sanofi pins hopes on new drugs after setbacks Reuters
01:30AM  Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day PR Newswire
01:02AM  Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma GlobeNewswire
01:01AM  Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
Dec-12-17 05:49PM  Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set Zacks
Dec-11-17 07:54AM  Biopharma Schizophrenia: High Demand For Innovation Vs. Pleas For 'Me-Too' Drugs Forbes
07:00AM  Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD PR Newswire
03:22AM  Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound? Zacks
Dec-08-17 09:36AM  The Zacks Analyst Blog Highlights: Netflix,, Constellation Brands and Regeneron Pharmaceuticals Zacks
Dec-06-17 01:18PM  This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November Motley Fool
Dec-04-17 04:18PM  Amgen, Regeneron Prep For Battle In 2018 Over Cholesterol Drugs Investor's Business Daily
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, and others for various product developments. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorFeb 09Sale325.601,000325,60012,000Feb 13 04:01 PM
Fenimore Christopher R.VP ControllerJan 16Option Exercise21.251503,188150Jan 17 04:07 PM
SING GEORGE LDirectorJan 02Option Exercise23.8415,000357,600134,772Jan 03 04:13 PM
YANCOPOULOS GEORGEPresident & CSODec 13Option Exercise21.92195,4384,284,001786,786Dec 13 05:17 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise21.92250,0005,480,000407,409Dec 13 05:17 PM
VAGELOS P ROYChairman of the BoardDec 11Option Exercise21.92153,9693,375,000483,512Dec 13 04:53 PM
BROWN MICHAEL SDirectorOct 05Option Exercise177.821,500266,7301,500Oct 05 04:18 PM
BROWN MICHAEL SDirectorOct 05Sale475.001,500712,5000Oct 05 04:18 PM
BAKER CHARLES ADirectorSep 29Option Exercise18.612,00037,22011,000Oct 03 04:00 PM
BAKER CHARLES ADirectorSep 29Sale450.002,000900,0009,000Oct 03 04:00 PM
Landry Robert ESVP Finance & CFOSep 06Sale497.62474235,8737,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 05Sale501.0618994,7007,573Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 01Option Exercise272.703,000818,10010,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOAug 31Sale493.43427210,6937,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 30Option Exercise272.702,000545,4009,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 23Sale476.45468222,9817,099Aug 24 04:47 PM
Landry Robert ESVP Finance & CFOAug 22Option Exercise272.702,000545,4009,099Aug 24 04:47 PM
VAGELOS P ROYChairman of the BoardAug 22Sale477.6431,94415,257,816329,543Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 21Sale470.3224,26911,414,076361,487Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 18Sale470.152,9001,363,435385,756Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 17Sale470.001,305613,350388,656Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Option Exercise21.92153,9693,375,000483,512Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Sale470.1710,9865,165,288389,961Aug 18 05:00 PM
Terifay Robert JEVP CommercialAug 10Option Exercise52.031,92199,95025,214Aug 11 04:02 PM
Landry Robert ESVP Finance & CFOAug 08Sale472.19526248,3727,099Aug 09 04:03 PM
Landry Robert ESVP Finance & CFOAug 07Option Exercise272.702,000545,4009,099Aug 09 04:03 PM
STAHL NEILEVP Research and DevelopmentJun 22Sale532.558,3064,423,33223,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 22Sale532.422,2691,208,0614,693Jun 23 04:10 PM
STAHL NEILEVP Research and DevelopmentJun 21Option Exercise30.6320,000612,60043,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 21Option Exercise30.634,500137,8359,193Jun 23 04:10 PM
BROWN MICHAEL SDirectorJun 20Option Exercise177.823,000533,4603,000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Option Exercise273.671,000273,67014,000Jun 21 04:12 PM
BROWN MICHAEL SDirectorJun 20Sale500.003,0001,500,0000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Sale500.011,000500,01013,000Jun 21 04:12 PM
Terifay Robert JEVP CommercialJun 16Sale468.1921,1479,900,81423,293Jun 19 04:44 PM
Terifay Robert JEVP CommercialJun 15Option Exercise52.0348,7502,536,46372,043Jun 19 04:44 PM
STAHL NEILEVP Research and DevelopmentJun 15Sale468.458,5674,013,17723,950Jun 16 04:36 PM
STAHL NEILEVP Research and DevelopmentJun 14Option Exercise21.2520,295431,26944,245Jun 16 04:36 PM
BROWN MICHAEL SDirectorJun 12Option Exercise177.822,000355,6402,000Jun 14 04:36 PM
BROWN MICHAEL SDirectorJun 12Sale474.452,000948,8900Jun 14 04:36 PM
GOLDSTEIN JOSEPH LDirectorJun 09Option Exercise273.671,000273,67014,000Jun 13 05:06 PM
GOLDSTEIN JOSEPH LDirectorJun 09Sale482.551,000482,55013,000Jun 13 05:06 PM
STAHL NEILEVP Research and DevelopmentJun 02Sale479.492,8121,348,31423,950Jun 05 04:52 PM
STAHL NEILEVP Research and DevelopmentJun 01Option Exercise198.3810,5442,091,72430,814Jun 05 04:52 PM
VAGELOS P ROYChairman of the BoardMay 25Sale458.149,2954,258,37383,652May 26 04:04 PM
BROWN MICHAEL SDirectorMay 12Option Exercise177.823,000533,4603,000May 15 04:07 PM
BROWN MICHAEL SDirectorMay 12Sale450.003,0001,350,0000May 15 04:07 PM
BROWN MICHAEL SDirectorMar 29Option Exercise177.821,000177,8201,000Mar 30 04:42 PM
BROWN MICHAEL SDirectorMar 29Sale400.001,000400,0000Mar 30 04:42 PM